Detailed Information on Publication Record
2022
Comparative analysis of transcriptomic points-of-departure (tPODs) and apical responses in embryo-larval fathead minnows exposed to fluoxetine
ALCARAZ, Alper James G., Shaina BARANIUK, Kamil MIKULÁŠEK, Bradley PARK, Taylor LANE et. al.Basic information
Original name
Comparative analysis of transcriptomic points-of-departure (tPODs) and apical responses in embryo-larval fathead minnows exposed to fluoxetine
Authors
ALCARAZ, Alper James G. (124 Canada), Shaina BARANIUK (124 Canada), Kamil MIKULÁŠEK (203 Czech Republic, belonging to the institution), Bradley PARK (124 Canada), Taylor LANE (124 Canada), Connor BURBRIDGE (124 Canada), Jessica EWALD (124 Canada), David POTĚŠIL (203 Czech Republic, belonging to the institution), Jianguo XIA (124 Canada), Zbyněk ZDRÁHAL (203 Czech Republic, guarantor, belonging to the institution), David SCHNEIDER (124 Canada), Doug CRUMP (124 Canada), Niladri BASU (124 Canada), Natacha HOGAN (124 Canada), Markus BRINKMANN (124 Canada) and Markus HECKER (124 Canada)
Edition
ENVIRONMENTAL POLLUTION, ENGLAND, ELSEVIER SCI LTD, 2022, 0269-7491
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
10511 Environmental sciences
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 8.900
RIV identification code
RIV/00216224:14740/22:00125954
Organization unit
Central European Institute of Technology
UT WoS
000760279500002
Keywords in English
Benchmark dose (BMD); Selective serotonin reuptake inhibitor (SSRI); Hazard assessment; Live-animal alternatives; New approach methodology (NAM)
Tags
International impact, Reviewed
Změněno: 10/10/2024 15:04, Ing. Martina Blahová
Abstract
V originále
Current approaches in chemical hazard assessment face significant challenges because they rely on live animal testing, which is time-consuming, expensive, and ethically questionable. These concerns serve as an impetus to develop new approach methodologies (NAMs) that do not rely on live animal tests. This study explored a molecular benchmark dose (BMD) approach using a 7-day embryo-larval fathead minnow (FHM) assay to derive transcriptomic points-of-departure (tPODs) to predict apical BMDs of fluoxetine (FLX), a highly prescribed and potent selective serotonin reuptake inhibitor frequently detected in surface waters. Fertilized FHM embryos were exposed to graded concentrations of FLX (confirmed at < LOD, 0.19, 0.74, 3.38, 10.2, 47.5 mu g/L) for 32 days. Subsets of fish were subjected to omics and locomotor analyses at 7 days post-fertilization (dpf) and to histological and biometric measurements at 32 dpf. Enrichment analyses of transcriptomics and proteomics data revealed significant perturbations in gene sets associated with serotonergic and axonal functions. BMD analysis resulted in tPOD values of 0.56 mu g/L (median of the 20 most sensitive gene-level BMDs), 5.0 mu g/L (tenth percentile of all gene-level BMDs), 7.51 mu g/L (mode of the first peak of all gene-level BMDs), and 5.66 mu g/L (pathway-level BMD). These tPODs were protective of locomotor and reduced body weight effects (LOEC of 10.2 mu g/L) observed in this study and were reflective of chronic apical BMDs of FLX reported in the literature. Furthermore, the distribution of gene-level BMDs followed a bimodal pattern, revealing disruption of sensitive neurotoxic pathways at low concentrations and metabolic pathway perturbations at higher concentrations. This is one of the first studies to derive protective tPODs for FLX using a short-term embryo assay at a life stage not considered to be a live animal under current legislations.
Links
LM2018127, research and development project |
| ||
LM2018140, research and development project |
| ||
LQ1601, research and development project |
| ||
90127, large research infrastructures |
|